Skip to main content
20 minutes minimum delay
toggle main navigation
Our Approach
Our Approach
NDMA Receptors
Therapeutic Area Focus
Pipeline
Clinical Studies
Investors
About Us
About Aptinyx
Leadership Team
Board of Directors
Working at Aptinyx
Contact Us
Site Search
Press Releases
Investor Relations
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Analyst Coverage
Financials & Filings
Quarterly Results
Annual Reports & Proxy
SEC Filings
Governance
Governance Documents & Charters
Executive Management
Board of Directors
Committee Composition
FAQ & Contacts
Investor Contacts
Investor FAQs
Investor Email Alerts
RSS Feeds
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
November 14, 2016
Aptinyx to Present Data for NYX-2925 in Models of Neuropathic Pain and Traumatic Brain Injury at Neuroscience 2016
Download
PDF format download (opens in new window)
November 10, 2016
Aptinyx Awarded Up to $2.85 Million in NIH Grants to Research NMDA Receptor Modulation for the Treatment of Neuropathic Pain and Age-Related Cognitive Decline
Download
PDF format download (opens in new window)
September 13, 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Download
PDF format download (opens in new window)
July 13, 2016
Aptinyx Initiates Dosing in Phase 1 Clinical Study of Lead NMDA-Receptor Modulator, NYX-2925
Download
PDF format download (opens in new window)
May 10, 2016
Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders
Download
PDF format download (opens in new window)